Vector Selection of a Quadripolar Left Ventricular Pacing Lead Affects Acute Hemodynamic Response to Cardiac Resynchronization Therapy: A Randomized Cross-Over Trial

Stefan Asbach¹, Maximilian Hartmann¹, Tobias Wengenmayer¹, Erika Graf², Christoph Bode¹, Juergen Biermann¹

¹University Heart Center Freiburg, Germany, ²Institute of Medical Biometry and Medical Informatics, University Medical Center, Freiburg, Germany

Abstract

Background: A suboptimal left ventricular (LV) pacing site may account for non-responsiveness of patients to cardiac resynchronization therapy (CRT). The vector selection of a novel quadripolar LV pacing lead, which was mainly developed to overcome technical issues with stimulation thresholds and phrenic nerve capture, may affect hemodynamic response, and was therefore assessed in this study. (German Clinical Trials Register DRKS00000573). Methods and Results: Hemodynamic effects of a total of 145 LVPCs (9.1 per patient) of CRT devices with a quadripolar LV lead (Quartet™, St. Jude Medical) were assessed in 16/20 consecutive patients by invasive measurement of LV+dP/dtmax at an invasively optimized AV-interval in random order. Optimal (worst) LVPCs per patient were identified as those with maximal (minimal) %change in LV+dP/dtmax (%ΔLV+dP/dtmax) as compared to a preceding baseline. LV+dP/dtmax significantly increased in all 145 LVPCs (p<0.0001 compared to baseline) with significant intraindividual differences between LVPCs (p<0.0001). Overall, CRT acutely augmented %ΔLV+dP/dtmax by 31.3% (95% CI 24%–39%) in the optimal, by 21.3% (95% CI: 15%–27%) in the worst and by 28.2% (95% CI: 21%–36%) in a default distal LVPC. This resulted in an absolute additional acute increase in %ΔLV+dP/dtmax of 10.0% (95% CI: 7%–13%) of the optimal when compared to the worst (p<0.0001), and of 3.1% (95% CI: 1%–5%) of the optimal when compared to the default distal LVPC (p<0.001). Optimal LVPCs were not programmable with a standard bipolar lead in 44% (7/16) of patients. Conclusion: The pacing configuration of a quadripolar LV lead determinates acute hemodynamic response. Pacing in the individually optimized configuration gives rise to an additional absolute 10% increase in %ΔLV+dP/dtmax when comparing optimal and worst vectors.

Introduction

Cardiac resynchronization therapy (CRT) has been shown to improve symptoms, quality of life, exercise capacity, and cardiac function and to reduce all-cause and heart failure morbidity and mortality in patients with heart failure, reduced ejection fraction, and cardiac dyssynchrony [1–6]. Therefore, in current guidelines [7], CRT is indicated for patients with depressed left ventricular (LV) function, NYHA class II–IV heart failure and a wide QRS complex. However, in the aforementioned large clinical trials, a large proportion of patients did not respond to therapy. This failure to respond may be due to inappropriate patient selection, progressive structural damage to the heart and/or suboptimal placement of the LV lead. Especially the latter has been subject to clinical [8] and experimental [9] studies, trials evaluating a multitude of endocardial pacing sites [10–12] and retrospective analyses of large multicenter trials [13,14]. Inconsistent findings suggest that the optimal pacing site may be specific to each patient and needs individual assessment. In line with this hypothesis, it has recently been shown that individually targeted LV stimulation, as defined by echocardiographic evaluation, can improve results of CRT [15].

While definition of non-response is matter of ongoing debate [16], treatment usually involves echocardiographic evaluation and modification of AV- and VV-intervals.

A novel quadripolar LV lead which offers ten left ventricular pacing configurations (LVPCs) has recently been shown to overcome technical issues with phrenic nerve capture and stimulation thresholds [17–19]. With a distance of 4.7 cm between the distal and proximal electrodes, it allows stimulation of the
ventricular myocardium along the selected tributary of the coronary sinus (CS) from a distal to a more basal region (Figure 1) and therefore offers additional options to modify device settings for hemodynamic reasons. However, hemodynamic consequences of these different LVPCs are largely unknown. Real life data has already shown that non-traditional LVPCs (i.e. LVPCs not programmable with standard bipolar leads) are used in a large number of patients, and it has been speculated that the choice is not only affected by pacing thresholds, but also by the perceived hemodynamic response [19].

We hypothesized that the hemodynamic response differs according to which LVPC is used and therefore affects response to CRT in the individual. We assessed this hypothesis by evaluating the acute hemodynamic response by invasive measurement of LV +dP/dt\textsubscript{max} in all possible pacing configurations in patients with clinical indication for CRT and by calculating the %change in mean LV +dP/dt\textsubscript{max} as compared to the preceding baseline (%ΔLV +dP/dt\textsubscript{max}).

### Methods

Between October 2010 and February 2012, twenty consecutive patients scheduled for implantation of a CRT device at University Medical Center Freiburg met inclusion criteria and were enrolled in the study. Written informed consent was obtained. The study protocol was approved by the local ethics committee. Inclusion criteria included heart failure NYHA II-IV despite optimal medical therapy, LV ejection fraction ≤ 35%, left bundle branch block with QRS width >130 ms and sinus rhythm at the time of implantation. The study is registered at the German Clinical Trials Registry (DRKS00000573).

#### Device Implantation

Device implantation was performed in the cardiac catheterization laboratory following a standard procedure. Briefly, after pocket preparation, the subclavian vein was used for vascular access. The ICD shock lead was screwed in the right ventricular (RV) apex in all patients. Subsequently, after an angiogram of the coronary sinus (CS) and its tributaries was performed, a lateral or posterolateral vein was accessed with a guide wire, over which the quadripolar LV lead (Quadra\textsuperscript{TM}, St. Jude Medical) was advanced into the prepared pocket. Device interrogation had to confirm stable and adequate lead measurements before the wound was closed. The device was programmed to VVI-40 back-up pacing until optimization.

#### Optimization

Invasive optimization was scheduled for the working day following device implantation. In the catheterization laboratory, the Pressure Wire\textsuperscript{®} Certus (St. Jude Medical) was placed in the left ventricle via a 5F femoral sheath and a guiding catheter, and then connected to the electronic control unit (RADI Analyzer\textsuperscript{®} Xpress, St. Jude Medical) and a personal computer for real-time assessment and storage of LV +dP/dt\textsubscript{max} (PhysioMon\textsuperscript{®} software version 2.02, Radi Medical Systems).

First, the optimal AV delay was assessed by measurement of LV +dP/dt\textsubscript{max} with the CRT-ICD programmed to a functional VDD modus with AV delays gradually increased from 40 to 300 ms (or appearance of intrinsic conduction) in 20–25 ms steps. These measurements were conducted with the LV lead programmed to a distal (D1M2) and proximal (P4M2) LVPC to exclude independence of AV delay and LVPCs. Subsequent biventricular pacing measurements were conducted at the individual optimal AV delay with simultaneous biventricular pacing. No VV-optimization was performed. All measurements started with a 120 s baseline period, followed by 120 s of VDD RV pacing. To minimize confounding effects, all possible LV lead configurations were assessed in random order as outlined below, each active for 120 s and each preceded by a 120 s baseline reference period without pacing to account for potential hemodynamic alterations over time. The optimal and worst pacing sites were defined as the sites which yielded the highest (lowest) value for mean LV +dP/dt\textsubscript{max} expressed as percent of the mean LV +dP/dt\textsubscript{max} in the preceding baseline period without pacing (%ΔLV +dP/dt\textsubscript{max}). Optimal versus worst and optimal versus default distal (D1M2) LVPC were compared per patient. The latter will be referred to as “distal” in the text and was chosen because it is the default programming of the device.

#### Statistical Analysis

After informed consent, the sequence of biventricular pacing configurations was assigned from a computer-generated randomization list by staff otherwise uninvolved, to guarantee treatment concealment. A Williams design was planned to exclude order effects, so that each pairwise sequence of pacing configurations would occur exactly twice in the 20 patients.

For each patient, absolute LV +dP/dt\textsubscript{max} measurements in all different LVPCs over the respective 120 s measuring periods were compared to the preceding baseline and to RV only pacing periods using the unpaired t-test. The distributions of %ΔLV +dP/dt\textsubscript{max}...
**Results**

**Implantation and Optimization**

In all 20 patients, the device was implanted without acute surgical complications. In all patients, a posterolateral position of the quadripolar LV lead could be achieved. In one patient, an increase of pacing threshold of the RV lead was noted one the day after surgery and was subsequently repositioned thereafter.

After informed consent, one patient refused invasive testing, one had spontaneous recovery of left bundle branch block to a proximal pacing configuration yielded optimal results. In one patient, an additional patient had to be excluded because of surgical complications. In all patients, a posterolateral position of the quadripolar LV lead could be achieved. In one patient, an increase of pacing threshold of the RV lead was noted one the day after surgery and was subsequently repositioned thereafter.

**Intraindividual Effects of LVPCs**

In each patient, all LVPCs improved LV +dP/dt max significantly as compared to the preceding baseline without stimulation (p<0.0001 for each of the 145 comparisons). Likewise, most LVPCs improved LV +dP/dt max significantly as compared to RV (VDD, AV-optimized) pacing (p<0.05 for 140/145 comparisons and p=ns for 5/145 comparisons).

We found no evidence of carry-over: Changes of mean baseline LV +dP/dt max over time were neither statistically significant (p=0.107) nor of a relevant magnitude (3% change from minimum 846.8±111.8 mmHg/s to maximum 871.8±112.1 mmHg/s). Optimal and worst LVPCs were identified as outlined above. Here, biventricular pacing acutely augmented LV +dP/dt max from 838.6±108.5 to 1097.2±161.5 mmHg/s in the optimal (p<0.0001), from 860.2±109.4 to 1040.3±143.9 mmHg/s in the worst (p<0.0001) and from 857.5±117.4 to 1085.1±160.4 mmHg/s in the distal LVPC (p<0.0001).

Overall effects between LVPCs were significantly different (p<0.0001 in every patient).

After application of correction for multiple comparisons, we found (by intraindividual comparison of all LVPCs as %ΔLV +dP/dt max) significant differences between optimal and worst LVPCs in all 16 patients (p<0.0001, Figure 3) and significant differences between optimal and distal LVPCs in 10/12 patients (p<0.0001, Figure 4, 4 patients had D1M2 as optimal LVPC). A difference in %ΔLV +dP/dt max of more than 10% was found in 6/16 (37.5%) of patients.

Distal LVPCs (D1 and M2 as cathode) more often showed optimal increment in %ΔLV +dP/dt max than proximal LVPCs (M3 and P4 as cathode) (12 (75%) versus 4 (25%), p=0.012), whereas proximal LVPCs by trend more often showed worst increment in %ΔLV +dP/dt max (10 (63%) versus 6 (37%), p=0.289). Please refer to Figure 5 for distribution of optimal and worst LVPCs.

When classifying by standard (D1M2, D1RV, M2RV) or non-standard (remaining 7) LVPCs, in 9 patients (56%) standard vectors and in 7 patients (44%) non-standard vectors resulted in optimal %ΔLV +dP/dt max (Figure 5, p=0.724). Two out of 4 patients with ischemic (50%) and 2 out of 12 patients with non-ischemic (16.7%) cardiomyopathy derived most benefit from a proximal (M3 or P4 as cathode) stimulations site (p=0.245).

When using a prespecified threshold of 10% increase in %ΔLV +dP/dt max as previously proposed [20], in 4 patients (25%) individually tailoring the optimal pacing configuration transferred non-responders into responders and thereby increased the overall response rate from 75% to 100% (Figure 3). Of note, in 3 of these 4 patients, non-standard and in 2 of these 4 patients, a more proximal pacing configuration yielded optimal results.

**Interindividual Effects of LVPCs**

Overall, biventricular pacing acutely augmented %ΔLV +dP/dt max by 31.3% (95% CI: 24%–39%) in the optimal, by 21.3% (95% CI: 15%–27%) in the worst and by 28.2% (95% CI: 21%–36%) in the distal LVPC. This resulted in a mean 10.0±5.1% (95% CI: 7%–13%) additional increase in %ΔLV +dP/dt max of the optimal when compared to the worst (p<0.0001) and a 3.1±3.1% (95% CI: 2%–5%) additional increase in %ΔLV +dP/dt max of the optimal when compared to the distal LVPC (p<0.0001).

All LVPCs were inferior to the mean of the best LPVC (p<0.05) and superior to the mean of the worst LPVC (p<0.01). There were no significant differences between LVPCs with the same cathode. Figure 6 illustrates the acute response to biventricular pacing in all possible LVPCs averaged over all patients.
Effects of Right-ventricular Pacing

Intraindividually, RV VDD, AV-optimized pacing produced a significant increase in LV $+\frac{dP}{dt}_{\text{max}}$ in 15/16 patients ($p<0.005$ for each comparison). Here, RV pacing acutely augmented LV $+\frac{dP}{dt}_{\text{max}}$ from $873.7\pm115.7$ to $942.4\pm124.9$ mmHg/s. In one patient, a significant decrease in LV $+\frac{dP}{dt}_{\text{max}}$ was noted ($p<0.0001$). Overall, this resulted in an increase of $6.7\pm8.1\%$ as compared to baseline.

Discussion

This study presents the first systematic, randomized investigation of acute hemodynamic effects of all different LVPCs of a commercially available quadripolar LV pacing lead. Our main findings are that (1) acute hemodynamic effects are determined by LVPCs leaving space for an additional average 10% absolute increase in %$\Delta$LV $+\frac{dP}{dt}_{\text{max}}$ when comparing optimal and worst LVPCs with (2) interindividual variations in response with respect to the optimal LVPC, which (3) in 44% of patients were LVPCs not programmable with a standard bipolar lead.
These findings may have implications on how to deliver optimal cardiac resynchronization therapy with a growing number of opportunities in modern CRT devices, may be of special value in the treatment of non-responders, and may form a concept on future LV lead developments.

Impact of LV Pacing Site

The initial evaluation of LV pacing sites by Butter et al. [8] revealed – by comparing two pacing sites that LV lateral free wall pacing was superior to anterior pacing and formed the currently followed concept of lateral or posterolateral LV pacing for most patients undergoing CRT therapy. This concept, however, has recently been challenged by animal studies in failing heart showing that lateral, but more anterior and apical pacing sites produced best CRT effect [9], studies in humans involving evaluation of multiple endocardial pacing sites in patients with ischemic [10,12] and non-ischemic cardiomyopathy [11,12], as well as retrospective analyses of large multicenter trials [13,14]. In accordance with these results, we found significant interindividual differences with respect to the optimal choice of the LVPC: We found differences of >10% in absolute $\%\Delta\text{LV} +dP/dt_{\text{max}}$in 38% of our patients with differences up to 22.9% in the individual.

In line with previous published data [10–12], the optimal configuration seems to be specific to each individual with the default distal LVPC being the optimal only in 4/16 patients. Therefore, it is easily conceivable that studies that evaluated CRT response at different sites within single CS tributaries did not find systematic, but substantial intrindividual differences with respect to the optimal pacing site [21,22].

Nowadays, epicardial LV stimulation via the CS is standard of care, even though, in the individual patient, sites not accessible via the CS may yield better response. This was specifically demonstrated by accessing the LV endocardium in 35 patients with nonischemic cardiomyopathy [11] and 11 patients with ischemic cardiomyopathy [10]. Derval et al. [11] found that (LV-only) pacing from within the CS augmented LV $+dP/dt_{\text{max}}$ by 15±23% to a significantly lower extent than the best endocardial site (31±26%). Spragg et al. [10] found an increase in LV $+dP/dt_{\text{max}}$ by CS pacing of 13% versus an average 36% increase with endocardial LV pacing in 7 patients with ischemic cardiomyopathy. The optimal pacing site here was often found in the extreme base of the LV. This site in most cases could not be stimulated with proximal vectors in our study, since, for stability reasons, the LV electrode was advanced until a distal wedge position was achieved. Possibly, further developments of LV multipolar electrodes might overcome this issue by adding some or increasing the distance between electrodes. However, as we now could show that individually programming a quadripolar lead adds an additional absolute 10% of $\%\Delta\text{LV} +dP/dt_{\text{max}}$ increase, this might already help to overcome some of the restraints linked to pacing in distal CS tributaries. It must also be acknowledged, that it is a complex and time-consuming procedure to individually assess a multitude of pacing sites from the endocardium, there is limited experience with permanently pacing the LV from the endocardial side [23,24], and optimal pacing sites may vary over time with changing activation patterns and/or cardiac geometry. The latter might at least in part be overcome by simple reprogramming of a multipolar electrode rather than by revision of an implanted endocardial lead.

Strategies to Define Optimal LV Pacing Site

As outlined above, results from many trials performed have shown that the location of the optimal pacing site shows significant interindividual variability and with a resulting need for individual assessment. Acute response to CRT as measured by LV $+dP/dt_{\text{max}}$ has been shown to be predictive of long-term response [20], however, this issue is still matter of debate [25], and, in fact, there is also evidence against this assumption [26]. Echocardiographically tailored stimulation of the LV seems to be able to increase the effect of CRT [15]. The TARGET Study [15] revealed that, as defined by echocardiography, about one third of optimal stimulation sites are located basally. In line with this, in our population 25% of patients exhibited best response when programmed to a more basally located LVPC, a proportion that might even increase if only patients with ischemic cardiomyopathy are regarded [10]. Stable lead position at these sites is hard to reach with standard, non-active fixation leads and may thus be more efficiently treated with proximal electrodes of a multipolar lead. A multipolar lead may also be reprogrammed with respect to
Hemodynamics of a Quadripolar LV Lead Vectors

Study Limitations
The study is limited by the small number and the heterogeneity of the included patients, therefore, measures, such as randomization of pacing sequence and multiple and lengthy baseline periods have been taken to control confounding effects. This extensive protocol might not be suitable for routine implementation in clinical practice. It must also be acknowledged that additional confounding effects, such as the severity of mitral regurgitation [29] and the amount of myocardial scar [30] affect CRT response and where not systematically assessed in this study. As noted above, acute hemodynamic response may not translate into chronic beneficial effects and may not be measurable with clinical endpoints.

References
1. Cazeau S, Lovelace G, Lavergne T, Walker S, Varma C, et al. (2001) Effects of multiventricular pacing in patients with heart failure and intraventricular conduction delay. N Engl J Med 344: 873–80.
2. Abraham WT, Fisher WG, Smith AL, Delurgio DB, Leon AR, et al. (2002) Cardiac resynchronization in chronic heart failure. N Engl J Med 346: 1845–53.
3. Young JR, Abraham WT, Smith AL, Leon AR, Lieberman R, et al. (2003) Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: the MIRACLE ICD Trial. JAMA 289: 2065-94.
4. Britton MR, Saxon LA, Boehmer J, Krueger S, Kass DA, et al. (2004) Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 350: 2140–50.
5. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, et al. (2005) The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 353: 1539–49.
6. Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, et al. (2009) Cardiac resynchronization therapy for the prevention of heart failure events. N Engl J Med 361: 3299–308.
7. Dickstein K, Vardas PE, Auricchio A, Daubert JC, Linde C, et al. (2010) 2010 Focused Update of ESC Guidelines on device therapy in heart failure: an update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. Eur Heart J 31: 2677–87.
8. Butterly C, Auricchio A, Stellbrink C, Fleck E, Ding J, et al. (2001) Effect of Resynchronization Therapy Stimulation Site on the Systolic Function of Heart Failure Patients. Circulation 104: 3026-9.
9. Helm RH, Byrne M, Helm PA, Daya SK, Osman NF, et al. (2007) Three-Dimensional Mapping of Optimal Left Ventricular Pacing Site for Cardiac Resynchronization. Circulation 115: 953-61.
10. Spragg DD, Dong J, Fetics BJ, Helm R, Marine JE, et al. (2010) Optimal left ventricular endocardial pacing sites for cardiac resynchronization therapy in patients with ischemic cardiomyopathy. J Am Coll Cardiol 56: 747–53.
11. Derval N, Steendijk P, Gola IJ, Deplange A, Labordeje J, et al. (2010) Optimizing hemodynamics in heart failure patients by systematic screening of left ventricular pacing sites: the lateral left ventricular wall and the coronary sinus are rarely the best sites. J Am Coll Cardiol 55: 566–75.
12. Paddeletti L, Peregolesi P, Riccardi G, Perrotta L, Grifoni G, et al. (2012) Acute Hemodynamic Effect of Left Ventricular Endocardial Pacing in Cardiac Resynchronization Therapy: Assessment by Pressure-Volume Loops. Circ Arrhythm and Electrophysiol 5: 460–7.
13. Saxou LA, Ohlshansky B, Volosin K, Steinberg JS, Lee BK, et al. (2009) Influence of Left Ventricular Lead Location on Outcomes in the COMPANION Study. J Cardiovasc Electrophysiol 20: 764–8.
14. Singh JP, Klein HU, Huang DT, Reek S, Kunnis M, et al. (2011) Left Ventricular Lead Position and Clinical Outcome Using the Midventricular Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MAFIT-CRT) Trial. Circulation 123: 1159-66.
15. Khan FZ, Virdie MS, Palmer CR, Pugh PJ, O’Halloran D, et al. (2012) Targeted left ventricular lead placement to guide cardiac resynchronization therapy: the TARGET study: a randomised, controlled trial. J Am Coll Cardiol 59: 1509–18.
16. Daubert JC, Saxon L, Adamson PB, Auricchio A, Berger RD, et al. (2012) 2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management. Heart Rhythm 9: 1524–1576.
17. Spersel J, Damschel W, Gutleben KJ, Kranig W, Mortensen P, et al. (2012) First prospective, multi-centre clinical experience with a novel left ventricular quadripolar lead. Euro pacing 14: 365-72.
18. Shetty AK, Duckett SG, Bostock J, Roy D, Ginks M, et al. (2011) Initial single-center experience of a quadripolar pacing lead for cardiac resynchronization therapy. Pacemaker Clin Electrophysiol 34: 484–9.
19. Forleo GB, Manica M, Di Biase L, Panattoni G, Della Rocca DG, et al. (2012) Clinical and procedural outcome of patients implanted with a quadripolar left ventricular lead: Early results of a prospective multicenter study. Heart Rhythm 9: 1822–1826.
20. Duckett SG, Ginks M, Shetty AK, Bostock J, Gill JS, et al. (2011) Invasive acute hemodynamic response to guide left ventricular lead implantation predicts chronic remodeling in patients undergoing cardiac resynchronization therapy. J Am Coll Cardiol 58: 1129–36.
21. Gold MR, Auricchio A, Hummel JD, Giudici MC, Ding J, et al. (2005) Comparison of stimulation sites within left ventricular veins on the acute hemodynamic effects of cardiac resynchronization therapy. Heart Rhythm 2: 376–81.
22. Shetty AK, Duckett SG, Liang Y, Kapetanakis S, Ginks M, et al. (2012) The acute hemodynamic response to LV pacing within individual branches of the coronary sinus using a quadripolar lead. Pacemaker Clin Electrophysiol 35: 196–203.
23. Bordachar P, Derval N, Ploux S, Garrigue S, Ritter P, et al. (2010) Left Ventricular Endocardial Stimulation for Severe Heart Failure. J Am Coll Cardiol 56: 747–53.
24. Whinnett Z, Bordachar P (2012) The risks and benefits of transseptal endocardial pacing. Curr Opin Cardiol 27: 19–23.
25. Prinzen FW, Auricchio A (2012) The “missing” link between acute hemodynamic effect and clinical response. J Cardiovasc Transl Res 5: 188-95.
26. Bogaard MD, Houthuizen P, Bracke FA, Doevendans PA, Prinzen FW, et al. (2011) Baseline left ventricular dP/dtmax rather than the acute improvement in dP/dtmax predicts clinical outcome in patients with cardiac resynchronization therapy. Eur J Heart Fail 13: 1126–33.
27. Cuoco FA, Gold MR (2012) Optimization of cardiac resynchronization therapy: importance of programmed parameters. J Cardiovasc Electrophysiol 23: 110–8.
28. Zhang Q, Fung J, Chan YS, Chan HC, Lin H, et al. (2008) The role of repeating optimization of atrioventricular interval during interim and long-term follow-up after cardiac resynchronization therapy. Int J Cardiol 124: 211–7.
29. Auricchio A, Schillingler W, Meyer S, Maisano F, Hoffmann K, et al. (2011) Correction of mitral regurgitation in nonresponders to cardiac resynchronization therapy by MitraClip improves symptoms and promotes reverse remodeling. J Am Coll Cardiol 58: 2103-9.
30. Delgado V, van Bommel RJ, Bertini M, Boelefls GJW, Marsan NA, et al. (2011) Relative merits of left ventricular dysynchrony, left ventricular lead position, and myocardial scar to predict long-term survival of ischemic heart failure patients undergoing cardiac resynchronization therapy. Circulation 123: 70–8.